Table 3.

Effect of adjusted-dose warfarin in patients with stage 3 CKDa

Adjusted-Dose WarfarinFixed, Low-Dose Warfarin + AspirinRelative Risk Reductionc (%) (95% CI); P
nNo. of Events2-year Rate (%)nNo. of Events2-year Rate (%)
Ischemic stroke/systemic embolismb
    eGFR ≥60 ml/min per 1.73 m224255.1259168.567 (10, 88); P = 0.02
    Stage 3 CKD26762.92492314.176 (42, 90); P <0.01
All major bleeds
    eGFR ≥60 ml/min per 1.73 m224256.325976.321 (−151, 75); P = 0.69
    Stage 3 CKD26752.524963.624 (−150, 77); P = 0.65
Deaths
    eGFR ≥60 ml/min per 1.73 m2242107.92591510.126 (−64, 67); P = 0.45
    Stage 3 CKD2672113.72492217.715 (−55, 53); P = 0.60
  • See Methods for definitions of stages of CKD. Features of stage 3 CKD participants did not differ significantly by treatment arm (see Supplmentary Table 1). CKD, chronic kidney disease; CI, confidence interval; eGFR, estimated GFR.

  • a 27 participants with stage 4 CKD are excluded.

  • b Almost all (96%) were ischemic strokes.

  • c Relative risk reduction estimated as 1 minus the hazard ratio.